GCP

Kirby McInerney LLP Reminds Investors of Lead Plaintiff Deadline in BioVie, Inc. (BIVI) Securities Class Action

Retrieved on: 
Wednesday, February 21, 2024
Scientific misconduct, Court, FDA, News, Macrocephaly, Alzheimer's disease, GCP, District court, Disease, Risk, Lung compliance, COVID-19, Patient, Clinical trial, Defendant, Pharmaceutical industry

Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until March 19, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • On November 8, 2023, the Company filed its quarterly report with the SEC on Form 10-Q for the quarter ended September 30, 2023.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

DEADLINE ALERT for CMI, MBLY, FTFT, BIVI: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, February 21, 2024
Suite, Investment, Class, Telephone, Macrocephaly, GCP, Defendant, Risk, Fintech, COVID-19, Good clinical practice, EyeQ, Law, Clinical trial, Security (finance), Hand

BENSALEM, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • BENSALEM, Pa., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at 888-638-4847 or by email to [email protected] .
  • Law Offices of Howard G. Smith

DEADLINE ALERT for MBLY, FTFT, BIVI, and BTI: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Wednesday, February 21, 2024
Complaint, Suite, Investment, Mobileye, Macrocephaly, Future, GCP, Defendant, Risk, BTI, Lung compliance, Fintech, American Tobacco Company, COVID-19, Good clinical practice, EyeQ, Law, Clinical trial, Security (finance), Hand

LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 21, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against BioVie Inc. - BIVI

Retrieved on: 
Tuesday, February 20, 2024
OSI, Scientific misconduct, Pomerantz, Court, Prior, News, Macrocephaly, GCP, Complaint, Lung compliance, Ext, Science, Good clinical practice, Patient, LLP, Action Replay, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against BioVie Inc. (“BioVie” or the “Company”) (NASDAQ: BIVI).
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • The class action concerns whether BioVie and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

BIVI INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioVie Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Tuesday, February 20, 2024
Court, Person, Macrocephaly, GCP, Complaint, Risk, COVID-19, Good clinical practice, Clinical trial

Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/BIVI .
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in BioVie you have until March 19, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Investors Sue BioVie (BIVI) After Potential Scientific Misconduct In Failed Phase 3 Clinical Trial Uncovered– Hagens Berman

Retrieved on: 
Monday, February 19, 2024
OSI, SAN, Scientific misconduct, Person, News, Macrocephaly, GCP, Risk, Lung compliance, Hagens Berman, COVID-19, Science, Good clinical practice, Patient, Pharmaceutical industry

SAN FRANCISCO, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .

Key Points: 
  • SAN FRANCISCO, Feb. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ: BIVI) investors who suffered substantial losses to submit your losses now .
  • The litigation focuses on the propriety of BioVie’s disclosures concerning its adherence to Good Clinical Practice (“GCP”) and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer’s disease drug.
  • ]” This news drove the price of BioVie shares down $1.25, or almost 30% lower, on Nov. 9, 2023.
  • “We’re focused on investors’ losses and are investigating whether BioVie may have intentionally concealed GCP and protocol violations,” said Reed Kathrein, the Hagens Berman partner leading the investigation.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against BioNTech, Mobileye, BioVie, and ADM and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 19, 2024
Complaint, Pfizer–BioNTech COVID-19 vaccine, BioNTech, Pfizer, OSI, FDA, News, Food, Mobileye, Growth, GCP, Risk, Q4, COVID-19, Good clinical practice, BNTX, EyeQ, ADM, Patient, Clinical trial, FY, Hand, Defendant, P.C

According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.

Key Points: 
  • According to the filed complaint, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and prospects.
  • As ADM was aggressively acquiring companies to expand its capabilities in Nutrition, investors were under the impression that the segment was growing rapidly.
  • As a result, ADM delayed its Q4 and FY 2023 earnings release and withdrew its outlook for the Nutrition segment.
  • For more information on the ADM class action go to: https://bespc.com/cases/ADM

Bitdefender Launches Powerful Cloud Security Posture Management Solution

Retrieved on: 
Thursday, March 7, 2024
Data Management, Security, IOT (Internet of Things), Technology, Software, Networks, Internet, Cloud, ISO, CSPM, Amazon Web Services, Access management, IAM, Identity, APRA, SOC 2, MDR, Identity management, Azure, ISO 27001, Linux, PCI DSS, GCP, Foot, Hypervisor, GDPR, Risk, EDR, Zero trust security model, Face, NIST, Organization, Policy, Platform as a service, Infrastructure as a service, XDR, Microsoft, SOC, Google Cloud Platform, AWS, PCI, Online shopping

Bitdefender, a global cybersecurity leader, today unveiled GravityZone CSPM+ , a powerful Cloud Security Posture Management (CSPM) solution for monitoring and managing configurations of cloud infrastructures including Amazon Web Services (AWS), Google Cloud Platform (GCP), Microsoft Azure and others.

Key Points: 
  • Bitdefender, a global cybersecurity leader, today unveiled GravityZone CSPM+ , a powerful Cloud Security Posture Management (CSPM) solution for monitoring and managing configurations of cloud infrastructures including Amazon Web Services (AWS), Google Cloud Platform (GCP), Microsoft Azure and others.
  • “GravityZone CSPM+ extends security, configuration management, and IAM capabilities across cloud infrastructures on a single platform - empowering businesses to proactively mitigate risks and strengthen overall security posture.
  • Additionally, GravityZone includes industry leading endpoint protection , container security with run-time support for containers and Linux kernel module independence, and security for servers , hypervisors, and virtualized environments – a true Cloud Native Security solution.
  • Genetics testing company NalaGenetics stated, “Right from the start, Bitdefender CSPM+ helped bridge the gap in terms of cloud infrastructure and security expertise.

Arrow Electronics Evolves ArrowSphere into Digital Distribution Platform to Reduce Complexity and Accelerate Growth in the IT Channel

Retrieved on: 
Tuesday, March 5, 2024
Software, Networks, Data Analytics, Hardware, Data Management, Professional Services, Technology, Apps, Applications, Cloud, Amazon Web Services, EDI, API, Azure, GCP, ARW, Arrow Electronics, Automation, Electronics, Heart, Microsoft, Arrow, Google Cloud Platform, Online shopping

Global technology solutions provider Arrow Electronics, Inc. (NYSE:ARW) today announced it has evolved its award-winning ArrowSphere platform into a full-service digital experience for its customers in North America.

Key Points: 
  • Global technology solutions provider Arrow Electronics, Inc. (NYSE:ARW) today announced it has evolved its award-winning ArrowSphere platform into a full-service digital experience for its customers in North America.
  • Based on customer feedback, the expanded ArrowSphere platform provides channel partners and vendors access to Arrow’s services through a single interface.
  • ArrowSphere MyBusiness streamlines and significantly speeds the quote-to-cash process and provides channel partners with real-time visibility into all their Arrow business and billing.
  • “At the heart of every successful digital ecosystem lies a platform that serves the needs of buyers, sellers, contributors and influencers.

  Cloud Governance Meets GenAI in New Thought-Provoking White Paper from CoreStack

Retrieved on: 
Tuesday, March 5, 2024
Professional Services, Data Management, Thought Leadership, Technology, Software, Artificial Intelligence, Internet, Cloud, Well, Data science, BCG, AI, Intelligence, Azure, Generative, GCP, GEOS, Metadata, OCI, Policy, VMware, Microsoft, McKinsey & Company, AWS

CoreStack, a global multi-cloud governance provider, today announced that it has published a new white paper titled “Cloud Governance Meets a Powerful Ally in Generative AI,” the latest in a series of thought leadership publications focused on revolutionizing the cloud governance landscape.

Key Points: 
  • CoreStack, a global multi-cloud governance provider, today announced that it has published a new white paper titled “Cloud Governance Meets a Powerful Ally in Generative AI,” the latest in a series of thought leadership publications focused on revolutionizing the cloud governance landscape.
  • Co-authored by CoreStack’s Chief Strategy Officer, Robert Ford, and Director of Data Science, Scott Tucker, the white paper examines the role of GenAI in cloud governance.
  • Cloud management is about doing things right, whereas cloud governance is about doing the right things right.
  • Visit www.corestack.io/white-papers to download this white paper and more thought leadership from CoreStack.